Online inquiry

IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2804MR)

This product GTTS-WQ2804MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ADCYAP1R1 gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 117
UniProt ID P41586
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2804MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ851MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ7832MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK 716155
GTTS-WQ12723MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ6671MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ3020MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ15252MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ13574MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ5884MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIFN
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW